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ABSTRACT: Chromomycin A3 ( C H R )  binding to the  duplex d(CAAGTCTGGCCATCAGTC)-  
d(GACTGATGGCCAGACTTG) has been studied using quantitative footprinting methods. Previous 
N M R  studies indicated CHR binds as a dimer in the minor groove. Analysis of autoradiographic spot 
intensities derived from DNase I cleavage of the 18-mer in the presence of various amounts of CHR revealed 
that the drug binds as a dimer to the sequence 5’-TGGCCA-3’, 3’-ACCGGT-5’ in the 18-mer with a binding 
constant of (2.7 f 1.4) X lo7 M-l. Footprinting and fluorescence data indicate that the dimerization 
constant for the drug in solution is -lo5 M-l. Since it has been suggested that CHR binding alters DNA 
to the A configuration, quantitative footprinting studies using dimethyl sulfate, which alkylates a t  N-7 of 
guanine in the major groove, were also carried out. Apparently, any drug-induced alteration in DNA 
structure does not affect cleavage by DMS enough to be observed by these experiments. 
ChromomycinA3 (CHR),’ Figure 1 (top panel), isa member 
of the aureolic acid class of anticancer drugs, which includes 
olivomycin and mithramycin (Miyamoto et al., 1967; Tatsuoka 
et al., 1960). On the molecular level these drugs exert their 
cytotoxic effects by binding to DNA, thereby interrupting 
transcription (Baguley, 1982). The binding process is facil- 
itated by Mg2+ and the interaction is believed to occur in the 
minor groove of DNA (Brikenshtein et al., 1983; Prasad & 
Nayak, 1976; Ward et al., 1965). 
Chromomycin and mithramycin have been the subject of 
numerous footprinting studies. Van Dyke and Dervan (1983) 
used the chemical cleavage agent Fe-MPE to show that CHR 
is able to recognize guanine- and cytosine-rich sites that are 
at least 3 base pairs in length. The affinity of sites was found 
to decrease in the order 5’-GGG, AGC > GCC, CCG > AGC, 
TCC, GTC-3’. The sequence AGC was found to have varying 
affinities, indicating the importance of flanking bases or the 
presence of nearby bound drug molecules. Strong binding of 
CHR to GC-rich sites was also observed in DNase I 
footprinting experiments (Fox & Howarth, 1985). As well 
as inhibiting DNase I cleavage within a binding site, CHR 
was found to enhance cleavage in AT-rich regions of DNA, 
where no drug binding takes place. The enhancements were 
attributed to DNA structural variations induced by the drug 
in the vicinity of its binding site. The study also showed that 
the reaction of dimethyl sulfate at N7 of guanine located in 
the major groove of DNA is modified in the presence of 
mithramycin. This prompted the authors to suggest that the 
drug may be binding in the major groove of DNA. 
Photofootprinting studies with U0z2+ indicated that mi- 
thramycin binds to GC-rich regions of DNA (Nielsen et al., 
1990). Areas surrounding drug binding sites showed enhanced 
cleavage, stlggesting that mithramycin is able to distort local 
DNA structure upon binding. 
Footprinting aiialysis of DNA fragments having (AT),, 
inserts (Cons & Fox, 1990) suggested that, when the inserts 
are adjacent to mithramycin binding sites, bound drug causes 
t We acknowledge the American Cancer Society, Grant NP-68 1 ,  for 
support of this research. 
Abbreviations: CHR, chromomycin A,; Fe-MPE, methidiumpropyl- 
EDTA-iron; DMS, dimethyl sulfate; TEAA, triethylammonium acetate; 
TE, 10 mM Tris.HC1 and 1 mM EDTA, pH 7.6. 
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FIGURE 1:  Structure of chromomycin A3 (top) and sequence of the 
18-mer with the dimer of chromomycin shown as a rectangle (bottom). 
the minor groove of DNA to open, changing it to a structure 
which is similar to A-DNA. This conclusion was based on 
enhanced cleavage of DNase I, DNase 11, and micrococcal 
nuclease at AT-rich sites adjacent to drug binding sites. All 
three aureolic acids, chromomycin, mithramycin, and olivo- 
mycin, have been studied using hydroxyl radical as a 
footprinting probe (Cons & Fox, 1989a,b). The drugs prefer 
to bind to the sequence GG via the minor groove of DNA. 
Additional insight on the structure of the CHR-DNA 
complex has recently been provided by NMR. Gao and Pate1 
(1989a,b) showed that, in the presence of MgZ+, CHR binds 
as a symmetrical dimer to the self-complementary duplex 
d[TTGGCCAA]2 with retention of 2-fold symmetry in the 
drug-DNA complex. The two CHR molecules share the 
minor groove at the center of the duplex in such a way that 
each hydrophilic edge of the chromophore is located next to 
a GG site. In addition, the drug-bound duplex appears to 
exist in the A-DNA conformation. 
0 1992 American Chemical Society 
Chromomycin-DNA Complex 
For the self-complementary duplex d[AGGATCCT] 2, the 
two preferred CHR binding sites, GG, are separated by an 
unpreferred site, AT. NMR studies show that, in the presence 
of Mg2+, CHR binds as a dimer to this duplex, but the resulting 
drug-DNA complex does not have a CZ symmetry axis. This 
suggests that binding to the preferred GG site forces half of 
the drug dimer to bind to the adjacent nonpreferred AT site 
(Gao & Patel, 1990; Leroy et al., 1991). 
Other NMRinvestigations (Banvilleet al., 1990a,b) showed 
that both mithramycin and chromomycin bind as symmetrical 
dimers to the duplex d(ATGCAT)2. The complexes possess 
CZ symmetry, and the drug undergoes slow chemical exchange 
on the NMR time scale. The fact that NOE contacts exist 
between the sugarsof the drug and several deoxyribose protons 
of DNA suggests that two pyranoses on one side of the aglycon 
are oriented along the sugar-phosphate backbone of G3-C4, 
while two other pyranoses are located near the backbone of 
As-T6. At a molar ratio of 1 drug/duplex, mithramycin 
exhibits chemical exchange cross-peaks allowing an estimate 
of 0.4 s-l to be made of its off-rate constant. Chromomycin 
also binds in a similar manner to the duplexes d[TATGCA- 
TA]2 and d[ATAGCTAT]2 but not to the duplex d[ATC- 
GAT12 (Banville et al., 1990a). Binding takes place in a 
widened minor groove, in contradiction to the earlier proposed 
major-groove model (Keniry et al., 1987). 
Although the NMR studies provide a detailed picture of 
the CHR-DNA complex, certain aspects of the binding 
mechanism remain unresolved. For example, it is not clear 
whether the drug binds as a preassociated dimer involving 
magnesium or whether it binds as a monomer, followed by 
cooperative binding of a second drug molecule to the adjacent 
DNA site. At the very low drug concentrations expected in 
a cell, one would expect most of the drug to be monomeric, 
so that monomers bound to DNA, and not dimers, would 
cause the cytotoxicity of chromomycin. In view of the recent 
interest in binding between DNA and dimers involving the 
aureolic acids and other agents such as distamycin (Pelton & 
Wemmer, 1989), we decided to study the CHR-DNA 
interaction using quantitative footprinting methods. Since 
this technique has the potential for studying binding at drug 
and DNA concentrations much lower than those normally 
used in NMR studies, it may permit observation of monomer 
binding to DNA. 
In this report we examine the binding of chromomycin A3 
to the duplex d(CAAGTCTGGCCATCAGTC)-d(GAC- 
TGATGGCCAGACTTG), Figure 1 (bottom panel), with 
quantitative footprinting methods, using as probes DNase I 
and dimethyl sulfate (DMS). The 18-mer contains the 
sequence 5’-TGGCCA-3’, earlier studied by Gao and Patel 
(1989a,b) using NMR methods. We derive information on 
whether monomer or dimer is involved in the binding 
mechanism from the analyses of the DNase I footprinting 
data and fluorescence measurements on the drug and its metal 
complex in solution. The results of the footprinting exper- 
iments with DMS shed light on whether the drug binds to the 
major or minor groove and on whether bound drug induces 
a structural change in DNA which is detectable with dimethyl 
sulfate. 
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Dyke & Dervan, 1983). All other chemicals wereused without 
further purification. 
The oligomers d(CAAGTCTGGCCATCAGTC) and 
d(GACTGATGGCCAGACTTG) were synthesized on a 1 .O- 
pmol scale by the DNA/Protein Core Facility, Department 
of Biology, Syracuse University, using standard 8-cyanoethyl 
phosphoramidite chemistry on a DuPont Coder 300 DNA 
synthesizer. Typical yields were 250%. Each oligomer was 
received with the resin attached and protected at the bases 
and phosphate groups of DNA. 
Purification of each oligomer was achieved as follows. 
Incubation of the sample in 1.5 mL of fresh ammonium 
hydroxide at 50 OC for 2 days separated the oligomer from 
the resin support and cleaved the 8-cyanoethyl, benzoyl, and 
isobutyl protecting groups. Aqueous NaOH was added to a 
final concentration of 5 mM, and the sample was evaporated 
to dryness. Chromatography using a DuPont Nesorb Prep 
cartrigde was used to detritylate the 5’-end of each oligomer 
and remove salts, failure sequences, and synthetic byproducts. 
For this procedure the DNA was dissolved in 16 mL of 0.1 
M triethylammonium acetate (TEAA), pH 7.0, and the 
separation was carried out on four 4-mL aliquots according 
to the Du Pont method. After washing of the cartridge with 
10 mL of MeOH and 5 mL of 0.1 M TEAA, 4 mL of oligomer 
was applied to the cartridge. Subsequent washings with 10 
mL of 12% CH3CN in 0.1 M TEAA, 25 mL of 0.5% aqueous 
trifluoroacetic acid, and 10 mL of 0.1 M TEAA were followed 
by elution of the DNA in 10 1 -mL fractions using 35% aqueous 
MeOH. Oligomer-containing fractions were identified by 
determining the absorbance of each solution at 260 nm. The 
yield of recovered product was 70%. The solvent was 
evaporated to dryness, and each 18-mer was reconstituted in 
250 pL of TE buffer (10 mM Tris and 1 mM EDTA), pH 
7.6. 
To remove contaminating oligomers less than 18 base pairs 
in length, aliquots containing approximately 10 OD units of 
DNA were loaded onto a 20% polyacrylamide gel containing 
6 M urea. After electrophoresis (Sambrook et al., 198q), the 
DNA was visualized by backshadowing the gel over a 20-cm 
X 20-cm Whatman PK5F silica gel plate containing a 
fluorescent indicator and exposing the gel to 254-nm light. 
Bands corresponding to the full-length oligomer were excised 
from the gel. DNA was recovered by crushing and soaking 
the polymer in TE buffer, pH 7.6, at 37 OC followed by 
lyophilization. Each oligomer was suspended in 6 mL of water 
for desalting with a Waters Sep-Pak C1g cartridge, and the 
procedure was carried out on 3-mL aliquots. After rinsing 
of the cartridge with 10 mL of CH3CN and 20 mL of water, 
3 mL of DNA solution was applied to the cartridge. The 
bound oligomer was washed with 10 mL of 25 mM aqueous 
ammonium bicarbonate, pH 8.0,lO mL of 25 mM ammonium 
bicarbonate, pH 8.0/5% aqueous CH3CN, and 20 mL of 5% 
aqueous CH3CN. Product was recovered by elution with 12 
mL of 30% aqueous CH3CN. The collected solution was 
lyophilized, and each oligomer was dissolved in 300 pL of TE 
buffer, pH 7.6. Total product recovery was -25%. 
Solutions of double-stranded DNA were prepared by heating 
equimolar amounts of each single-stranded oligomer at 90 OC 
for 10 min and cooling slowly over 2-3 h to room temperature. 
Molar extinction coefficients of 168 000 cm-I M-1 for the 
C-rich oligomer and 173 000 cm-1 M-I for the G-rich oligomer 
were calculated from reported values for extinction coefficients 
of individual nucleotides and the sequence of the oligomer 
(Borer, 1975). All DNA solutions were stored at -20 OC. 
The C- and G-rich oligomers were labeled at their 5’ ends 
EXPERIMENTAL PROCEDURES 
Chromomycin A3 was purchased from Sigma and used 
without further purification. Solutions of the drug in ethanol 
were stored at 4 OC in the dark until needed. Drug 
concentrations were determined by UV-vis spectroscopy using 
the reported value of c = 39 800 cm-l M-I at 282 nm (Van 
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FIGURE 2: Autoradiogram showing DNase I cleavage of the 18-mer labeled at position 1 (C) in the presence and absence of chromomycin 
A3. Lane 25 shows cleavage by HueIII, lane 26 shows cleavage by DNase I (no CHR), and lane 27 is DNA alone (no drug or enzyme). Lanes 
1-15 show cleavage in the presence of increasing concentrations of CHR in the order listed in Experimental Procedures. The remaining lanes, 
16-24. have CHR concentrations in the range 8.92-14.86 uM and were not used in the analysis. A partial sequence of the 18-mer is given 
at the'left of the autoradiogram. 
using [y-32P]ATP/T4 polynucleotide kinase and purified via 
electrophoresis in a 20% polyacrylamide gel containing 6 M 
urea (Sambrook et al., 1989). Solutions of single end-labeled 
double-stranded oligomer with the label at position 1 (C), the 
C 18-mer, or position 18 (G), the G 18-mer (see Figure 1, 
bottom panel), were prepared by hybridizing the cold strand 
to the hot strand in the manner earlier described. 
DNase I footprinting reactions were performed on the C 
18-mer in a total volume of 12 pL, for 15 min at 37 "C, in 
a buffer consisting of 10 mM Tris, pH 7.6,25% ethanol, 0.33 
mM EDTA, 8 mM MgC12, and 2 mM CaC12. The footprinting 
experiments were performed twice. In the first experiment 
the final total drug concentrations present in solution were 
0.15,0.30,0.45,0.59,0.74, 1.49,2.23,2.97,3.72,4.46,5.20, 
5.94,6.69,7.43, and 8.17 pM. In the second experiment, the 
concentrations were 0.1, 0.2, 0.3,0.4, 0.5,0.6,0.7,0.8,0.9, 
1.0, 1.2, 1.4, 1.6, 1.8,2.0,2.2,2.4,2.6,2.8,3.0,5.0, and 10.0 
pM. Drug was preincubated with DNA for 2 h at 37 "C prior 
to addition of the enzyme. The final concentration of DNA 
duplex present in all experiments was 2 pM, and the enzyme 
concentration was between 8 X le2 and 8 X l e 3  unit/pL. 
Assuming that all of the protein present is DNase I in the 
commercial preparation of the enzyme, the concentration of 
DNase I present in the various reactions was 10-7-10-8 M. 
Reactions were quenched by addition of 6 pL of denaturing 
formamide loading buffer (Sambrook et al., 1989) and stored 
at -78 "C until the start of electrophoresis. Sequence was 
established by HaeIII cleavage of the C 18-mer in a total 
volume of 12 pL for 1 h at 37 "C. The final concentration 
of DNA was 2 p M  in duplex, and the HaeIII concentration 
was about 0.21 unit/pL. Aliquots of reactions were heated 
to 90 O C  and loaded onto 25% (19:l w/w acrylamide/ 
bisacrylamide) polyacrylamide gels containing 6 M urea. DNA 
fragments were separated by electrophoresis at 55 "C using 
an in-house-developed electrophoresis device. A Molecular 
Dynamics 300A computing densitometer was used to scan 
autoradiograms to yield whole-area spot integrations (volumes) 
proportional to DNA concentrations. The autoradiogram for 
the first footprinting experiment is shown in Figure 2. The 
sum of volumes of all the cleavage products as a function of 
drug concentration is shown in Figure 3. Individual spot 
intensities as a function of drug concentration ( footprinting 
plots) are given in Figures 4 and 5 .  The autoradiogram for 
the second DNase I experiment is shown in Figure 6. 
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FIGURE 3: Total-cut plot for first DNase I footprinting experiment 
(Figure 2), with linear fit. 
In separate reactions, dimethyl sulfate/piperidine foot- 
printing studies were performed using the C 18-mer duplex 
labeled at C and G 18-mer duplex labeled at G. These were 
done in a total volume of 12 pL, for 5 min at 37 "C, in a buffer 
consisting of 6 mM Tris, pH 7.6,7.5%ethanol, 0.6 mM EDTA, 
and 8 mM MgC12. The final drug concentrations for the 
studies involving the C 18-mer were 0.005, 0.01, 0.05, 0.1, 
0.5, 1.0 (0.25) 5.0, 10, 15, 25, and 50 pM. The same 
concentrations were used for the G 18-mer. Drug was 
preincubated with 2 pM of duplex for 2 h at 37 OC, followed 
by addition of dimethyl sulfate to a final concentration of 
1.7% (v/v). After incubation at  37 OC for 5 min, reactions 
were quenched with DMS stop solution (Sambrook et al., 
1989) chilled to 0 "C. To help precipitate DNA samples 
during subsequent purification, 4 mg ( 1 mg/pL) of an aqueous 
solution of calf thymus DNA was added. DNA was recovered 
by ethanol precipitation as previously described (Sambrook 
et al., 1989). Dried samples were incubated in 100 pL of 1 
M aqueous piperidine for 30 min at 90 OC. The reaction 
products were evaporated to dryness, ethanol-precipitated, 
and lyophilized as above. DNA was resuspended in 10 pL of 
denaturing formamide loading buffer, heated to 90 "C for 5 
min, and electrophoresed in denaturing polyacrylamide gels 
as in the DNase I footprinting experiments. The resulting 
autoradiograms were scanned with a Molecular Dynamics 
densitometer. 
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FIGURE 4: Total-cut corrected footprinting plots (solid symbols) for 
drug-blocked sites with theoretical fits (open symbols). Data derived 
from Figure 2. Model includes dimer binding and dimerization in 
solution. 
Fluorescence spectra of chromomycin A3 were recorded on 
a Hitachi F-4010 fluorescence spectrophotometer. For mea- 
surements in a solvent system consisting of 10 mM Tris buffer, 
pH 7.6,0.33 mM EDTA, 8 mM MgC12, 2 mM CaC12, and 
25 % EtOH, emission spectra were recorded from 408 to 700 
nm using an excitation wavelength of 408 nm. Spectra of 
drug solutions in the same solvent system, but without MgC12, 
were obtained in the same manner. 
ANALYSIS 
Establishingthe Model. Examination of the experimental 
DNase I footprinting plots (intensity of cut fragment vs total 
drug concentration) showed a decrease in cutting with added 
drug for sites 7 through 15, ascribed to the classic footprinting 
phenomenon: bound drug prevents DNase I from cleaving. 
8oooj 72001 
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FIGURE 5:  Experimental footprinting plots for cleavage of sites 5 
and 6, with calculated plots (open symbols) from model including 
dimer binding and dimerization in solution. 
The enzyme possesses a small loop which blocks cleavage 
about 3 base pairs to the 3' side of a drug binding site (Suck 
& Oefner, 1986). Since the inhibition length is 9 base pairs 
long and the loop on the enzyme is - 3 base pairs, our results 
are consistent with a drug dimer covering the sequence 5'- 
TGGCCA-3' of the 18-mer. The footprinting plots for sites 
5 and 6, outside of the drug binding site, do not show inhibition. 
Intensities for site 5 ,  which is farthest from the drug binding 
site, are roughly constant with added drug while site 6 shows 
a sharp increase near 3 pM drug followed by a decrease after 
about 5 pM. Sites 1-4 of the 18-mer are not cleaved by DNase 
I, because the affinity of the enzyme for the ends of DNA is 
low (Suck & Oefner, 1986), and sites 16-17 are weakly 
cleaved. Due to their low intensity and proximity of their 
spots to the parent band, they were not used in the analysis. 
The total cut (sum of intensities for cutting at sites 5-15, 
and not including the parent band) for the first DNase I 
experiment was plotted against chromomycin concentration 
(Figure 3). Since most of the observed sites show decreased 
cleavage, the total cut It decreases as drug concentration 
increases. It is fit adequately by the linear function It = 20094 
- 1617[CHR]. To correct for gel loading and other errors, 
all spot intensities for each drug concentration are multiplied 
by the ratio of It to the actual total cut for that concentration. 
With two exceptions, the correction factors differ from unity 
by 12% or less. The resulting intensities are shown in Figures 
4 and 5 .  The total cut for the second footprinting experiment 
(Figure 6) was fit to the linear function I{ = 3595.4 - 239.2- 
[CHR]. Spot intensities for each drug concentration were 
corrected using It'. Footprinting plots (not shown) resemble 
those for the first experiment. 
Enlightening information about binding of drug molecules 
to the fragment may be obtained from the initial relative slopes, 
calculated by fitting intensities for the first n drug concen- 
trations to a straight line and dividing the slope by the intercept. 
The value of n must be large enough to give a significant 
variation in intensity but not so large that the footprinting 
intensities vary nonlinearly with drug concentration. We have 
tried several values of n; the conclusions drawn from the initial 
relative slopes are the same. Results for n = 1 1, corresponding 
to drug concentrations from 0.1 to 5.2 pM, are shown in Figure 
7. The error bars give the uncertainty in each initial relative 
slope, calculated from the least-squares fit. 
The cleavage inhibition for sites 7-15 is shown clearly by 
the negative slopes. The large drug-induced enhancement in 
cleavage for site 6 is evidenced by the large positive slope, 
while the small slope for site 5 reflects the near-constancy of 
the intensity for this cleavage product. Furthermore, we note 
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FIGURE 6: Autoradiogram for DNase I cleavage of the 18-mer labeled at position 1 (C) in the presence and absence of chromomycin A3. Lane 
26 shows cleavage by HaeIII, lane 3 shows cleavage by DNase I (no CHR), lane 1 shows DNA alone (no drug or enzyme), and lane 2 shows 
DNA alone (no drug or enzyme) heated to 37 "C for a total of 2 h 15 min and then to 90 OC for 5 min according to the footprinting research 
protocol. Lanes 4-25 show cleavage in the presence of increasing concentrations of CHR, in the order listed in Experimental Procedures. A 
partial sequence of the 18-mer is given at the right. 
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FIGURE 7: Relative initial slopes of footprinting plots as a function 
of sequence. 
that, within the uncertainties due to the scatter in the data, 
the slopes may be the same for all sites in the inhibition region. 
The inhibition region could result from two monomer binding 
sites, such that a drug bound at the first blocks sites 7-12 
from cleavage, including 3 base pairs for the loop on DNase 
I (Suck & Oefner, 1986), and a drug bound to the second 
blocks cleavage at sites 10-15. The fact that initial relative 
slopes are the same for all sites means that the binding constants 
are not very different for the two binding sites. 
Now if there were two monomer binding sites, cleavage at 
positions 10-12 would be blocked by drug binding at either 
site, and the footprinting intensities for these cleavage sites 
would decrease faster with drug concentration than intensities 
for cleavage sites blocked by only one drug binding event. The 
initial relative slopes show this is not the case, and we can rule 
out monomeric binding of drug to the 18-mer. Calculations 
for models allowing for independent monomer binding bear 
this out: this model cannot fit the data. The sum of squared 
deviations between experimental and calculated intensities 
(D, eq 1) is greater than 5 X lo6, whereas models including 
dimer binding (see below) give D - lo5. 
The reason that there is essentially no DNA fragment with 
monomer bound could be (1) unbound drug in solution exists 
only in the form of dimer or (2) the binding is highly 
cooperative. In the latter case, the binding constant of a drug 
molecule to DNA is much higher when the DNA has already 
bound one drug molecule than when no drug is bound, so it 
is very unlikely to find a DNA fragment with only one drug 
bound. This is the situation for the anticancer drug actino- 
mycin D interacting with the duplex [d(CGTCGACG)]* 
(Snyder et al., 1989). To determine whether dimerization of 
chromomycin occurs in solution, we analyzed the footprinting 
intensities for sites 7-15 by a model including drug dimer- 
ization as well as drug binding. 
Let I i j  be the spot intensity for the ith site and thejth drug 
concentration as calculated from a model. will depend on 
one or more nonlinear parameters such as equilibrium 
constants. The values of such parameters are obtained by 
minimizing the deviation between calculated and measured 
intensities: 
D = (1) 
ij 
For the first data set, for which there are 15 drug concentrations 
and 9 sites (only the binding sites are considered), D is a sum 
over 135 points. The minimization of D with respect to 
nonlinear parameters is carried out by the Simplex procedure 
(Fletcher, 1980). By comparing the lowest values of D for 
different models applied to the same data set one can judge 
whether one model is significantly better than another. 
The intensity for spots resulting from cleavage at  site i (i 
= 7-15) is proportional to the probability that a duplex has 
no dimer bound and to the amount of available probe at  the 
site. Since binding of drug to some duplexes prevents binding 
of the cleavage agent, it increases probe concentration in bulk 
solution and on duplexes where no drug is bound. When the 
rate of cleavage is limited by available probe, the cleavage 
may be substantially enhanced. This "mass-action enhance- 
ment" (Ward et al., 1988; Goodisman & Dabrowiak, 1992) 
may be taken into account by multiplying the calculated spot 
intensity by an enhancement factor, calculated by assuming 
the amount of probe bound to all DNA sites remains constant 
with drug concentration. This implies that the total cut does 
not change with drug concentration, as has been observed in 
numerous footprinting experiments. However, this does not 
Chromomycin-DNA Complex 
obtain in the present case, as seen in Figure 3, so the mass- 
action model is not usable here. Instead, we consider the 
probe-DNA binding equilibria explicitly, as was done pre- 
viously in treating binding to a single site (Rehfuss et al., 
1990). 
The drug-binding equilibria that must be taken into account 
are the following: 
CHR + CHR F? CHR, (2 )  
Biochemistry, Vol. 31, No. 38, 1992 9315 
ui and u j  for each value of ct. Then, calculated intensities are 
CHR, + N F? CHR2N (3) 
Here, CHR is unbound drug monomer, CHR2 is unbound 
drug dimer, N is the 18-mer, and CHR2N is the 18-mer duplex 
with bounddrug dimer. Theequilibrium CHR + N F? CHRN 
is not considered, since [CHRN] is not measurable, and 
consideration of this equilibrium would introduce an additional 
equation and an additional unknown. The equilibrium between 
CHRN, CHR, and CHRNz is a combination of the others. 
Binding of Preexisting Dimer to 16mer.  We first suppose 
the dimerization constant is so large that only dimer is present 
in solution; the binding equilibrium, eq 3, is written 
(4) 
where Cb is the concentration of duplexes with dimer bound, 
N is the total concentration of oligomers (2 pM), and co is the 
concentration of unbound dimers. If ct is the nominal total 
drug concentration, expressed as monomer 
This could be solved for co for each ct, giving the probability 
that a duplex has no drug dimer bound as 1 - cb/N. 
We must also consider the probe-binding equilibrium. 
Suppose there are n probe sites per oligonucleotide, m of which 
are blocked by a bound drug dimer. The n sites include sites 
for which cleavage intensities are not measured (i.e., 15-17). 
Let u0 be the fraction of oligomers with neither drug nor probe 
bound, Ub the fraction with drug alone bound, vi the fraction 
with a single probe molecule bound at probe site i ( i  = 1-n), 
and u j  the fraction with a drug dimer bound and a probe 
molecule bound at probe site i [ i  = ( m  + 1)-n]. We assume 
the foregoing represent all the possibilities, so that, for example, 
there is never more than one probe bound to a DNA fragment; 
therefore, u0 + Ub + nul + ( n  - m )  u j  = 1. In terms of eqs 4 
and 5 ,  Cb = Nub + ( n  - m)Nuj.  Assuming that the binding 
constant for drug is the same whether or not a probe molecule 
is bound to the fragment (at a site from m + 1 to n ) ,  the 
equilibrium equations are 
- K, = Nub 
NU,('/,C, - NU, - ( n  - m)Nuf) 
Nu,' 
N u , ( ' / ~ c ,  - NU, - ( n  - m)Nu,') ( 6 )  
Nui 
Nuo(Pt - Nnu, - N(n - m)u,') Kp = (7) 
where Kp is the binding constant for probe and PI is the total 
probe concentration. The above equations are solved to obtain 
1, = A;ui 
for i = l-m and 
lij = A,'(Ui + u,') (8b) 
for i = ( m  + 1)-n. The values of the linear parameters A / ,  
which are proportional to digest time and cutting rate 
constants, and thus different for different sites, are determined 
in the minimization of D. Sites from m + 1 to n will 
automatically show the mass-action enhancement, if it exists, 
since ui and u j  are calculated taking into account the probe- 
binding equilibrium. 
The nonlinear parameters are K1, Kp, and Pt. In principle, 
all could be found from the minimization of D, eq 1, but 
because of dependence between the parameters the data are 
not sufficiently precise to yield reliable values. One can 
estimate Kp as 2 X lo4 M-' (Rehfuss et al., 1990) and Pt as 
1 X M (see above) and find only K1 by minimization of 
D. The resulting value of K1 is 5.2 X lo6 M-l, with D = 3.0 
X lo6. If Pt is fixed at lo-' M and the other two parameters 
are varied, we find K1 = 7.1 X lo6 M-l, Kp = 1.2 X lo5 M-l, 
andD= 2.4X lo6. If 10-8MisusedforPt,wefindaminimum 
Dof 2.3 X lo6 with K1 = 7.1 X lo6 M-l and Kp = 1.1 X lo5 
M-l . If Kp is fixed at  2 X 1 O4 M-l, variation leads to a minimum 
Dof 2 X lo6 with K1 = 7 X lo6 M-l and PI = 3 X lo-* M. 
Of course, if both Kp and PI are varied (as well as K1) to 
minimize D, one can reduce D somewhat, to 1.9 X lo6, but 
three variable parameters are now involved, and the decrease 
in D is insufficient to place confidence in values for all three 
parameters. (The values obtained are K1 = 7.0 X lo6 M-l, 
Kp = 1.1 X lo5 M-l, and Pt = 1.4 X M). Using the 
second data set, we find K1 = 2.1 X lo6 M-l by minimizing 
D, keeping PI = 5 X M and Kp = 2 X lo4 M-l. Here, 
D is 1.55 X lo5 and its value cannot be reduced much by 
changing the assumed values of Kp and PI. With PI = 1 X 
l e 7  M, the minimum D is 1.53 X lo5, obtained with K1 = 
2.0 X lo6 M-l. 
The Drug Monomer-Dimer Association. To consider the 
possibility of monomers existing in solution, we introduce the 
equilibrium constant K3 which describes monomer-dimer 
association outside of DNA, eq 2: 
(9) 2 K3 = co/cm 
As before, co is the concentration of drug dimer in solution, 
and cm is the concentration of drug monomer in solution. The 
equilibrium between unbound drug monomer and drug 
monomer bound to DNA is not considered because, as shown 
above, bound monomer is of negligible importance. The total 
drug (monomer) concentration is now 
This model becomes equivalent to the previous one for large 
K3. Equation 10 is rewritten as 
C. 
L 
co = 
2 + (K3c0)-'/' + 2NK1( 1 + K1co)-' 
and solved iteratively to obtain co for each ct, KI, and K3. 
Calculated spot intensities are given by eq 8. 
We now minimize D, eq 1, with respect to the two nonlinear 
parameters, K, and K3, associated with dimer binding to the 
18-mer and the monomer-dimer drug association in solution, 
respectively. Again we take PI = 1 .O X l k 7  M and K, =: 2.0 
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X lo4 M-l. We find D = 1.9 X lo6, K1 = 3.5 X lo7 M-l, and 
K3 = 6.4 X lo4 M-l. The decrease in D from 3.0 X lo6 (found 
assuming all drug is in the dimeric form; previous section) is 
large, indicating the value of K3 is significant. For the second 
data set, variation Of  K3 leads to a decrease in D to 1.2 X lo5. 
To estimate errors, we find how much K1 or K3 must be changed 
to increase D by 10%. This procedure gives, for the first data 
set, K1 = (3.5 f 1.8) X lo7 M-l and K3 = (6.0 f 3.0) X lo4 
M-l. For the second data set, this procedure gives K1 = (2.3 
f 1.5) X 108 M-l and K3 = (4.0 f 3.0) X lo3 M-l. It should 
be added that uncertainties in parameters are underestimated, 
since, if one changes K1 and K3 simultaneously, their values 
can be changed by more than the above, with only a small 
change in D. 
The self-association constant of chromomycin, K3, is 
considerably higher than that found for the anticancer drug 
daunomycin, - lo2 M-l (Chaires et al., 1982). However, at 
concentrations of <1 pM the drug exists mostly as a monomer 
in solution. Thus, the binding of two drugs to the 18-mer is 
most likely the result of the binding of one drug followed by 
the cooperative binding of a second drug rather than binding 
of a preassociated dimer to the duplex. 
Analysis of the Fluorescence Data. The monomer4mer 
equilibrium can be investigated by fluorescence intensity 
measurements. If fluorescence intensity is proportional to 
the nominal drug concentration (Beer’s law), it is probable 
that only one fluorescent species is present. Deviations from 
Beer’s law imply the presence of more than one species, such 
as monomers and dimers, in equilibrium with each other in 
solution. 
Assuming an equilibrium between two monomers and a 
dimer, we have 
(1 1) 
where ct is the nominal drug concentration. Combining eq 11 
with the dimerization equilibrium equation (eq 9), we can 
solve for cm and CO. Writing the fluorescence due to monomers 
as UmCm and that due to dimers as adCO, we have for the total 
c, = c, + 2c0 
)+ 
( 8K3 
f = a ,  (-1 + (14: f (K3q)1/2  
) (12) 1 + 4K3ct - (1 + 8K3cJ1/* 
If ad = 2am, f becomes just Umc, independently of 4, but if 
&J # 2a,, the deviation from linearity in a plot off vs c yields 
information about &. If K3 is small (no dimers) one will have 
f amct, while if K3 - co (no monomers) one will have f = 
intermediate K3 values make f nonlinear in ct. For 
small ct, it is appropriate to expand the square roots in eq 12 
as power series in ct, giving 
f = UmCt + (ad - ~u,)K~c,Z - 2(ad - 2U,)K:Ct3 + ... (1 3) 
Thus, a fit of experimentalfto a power series in ct will permit 
determination of the three parameters in eq 13, a m ,  (Id, and 
K3. One could try to fit eq 12 directly, but one would not be 
able to assess the effect of increased number of terms as in 
the power series. 
Figure 8 shows fluorescence intensities at 664.8 nm for 
chromomycin concentrations up to 2.8 pM in the absence of 
Mg2+ and up to 5.5 pM in the presence of 8 mM Mgz+. In 
the latter case, the sum of the squares of residuals is 0.071, 
0.031, or 0.030 for linear, quadratic, or cubic fits. Thus, the 
intensity is clearly nonlinear in concentration, but the cubic 
term is small and hence difficult to determine accurately. The 
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FIGURE 8: Fluorescence intensity as a function of nominal drug 
concentration, with and without Mgz+. Cubic polynomial fits are 
shown. 
polynomial coefficients are -0.020, 0.280, 0.0383, and 
-0.00241, so that, from eq 13, -2K3 = -0.00241/0.0383 and 
K3 = 3.2 X lo4 M-l. However, the uncertainty is large: if 
we eliminate the data point for 5.5 pM, the sum of squares 
of residuals is reduced to 0.0034, suggesting that this point 
is in error. The coefficients are -0.005, 0,110, 0.177, and 
-0.0280, which makes K3 = 7.9 X lo4 M-l. This is of the 
same size as the value from analyses of the footprinting data. 
The effects of Mgz+ on oligomerization of CHR in the 
absence of DNA have previously been studied. Hayasaka 
and Inoue (1969) used sedimentation equilibrium to show 
that, in the presence of Mgz+ and high (1 mM) concentration 
of the drug, aggregates corresponding to tetramers and 
pentamcrs formed in solution, Calcium ion, also present in 
the buffer used in the study, apparently has little affinity for 
the drug (Itzhaki et al., 1990) and does not facilitate drug 
binding to DNA as does Mg2+ (Cons & Fox, 1989a,b). 
Fluorescence intensities in the absence of Mg2+ (lower plot 
of Figure 8) are analyzed in the same way. The sums of 
squares of residuals for linear, quadratic, and cubic fits are 
0.217,0.039, and 0.012, so the intensitiesareclearly nonlinear 
in concentration. The coefficients for the cubic fit are 0.038, 
-0.023,0.8936, and 0.173, giving K3 = -(-0.173)/ [(2)(0.836)] 
= 1.0 X lo5 M-l, essentially the same as, but slightly higher 
than, the value derived for Mg2+ present. The plot shows the 
cubic fit. K3 is the same with and without MgZ+, to 10% or 
so, which is the error in the measurement from fit of data. If 
K3 = 1.0 X lo5 M-l, the drug is 85% monomeric at ct = 1 pM 
and 53% monomeric at ct = 8.17 pM. 
Dimethyl Sulfate Cleavage of the 18-mer. Footprinting 
experiments were performed for DMS/piperidine cleavage of 
the DNA fragment. Because cleavage by DMS takes place 
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influence the alkylation rate of DMS (Nielsen, 1990), 
chromomycin binding to the 18-mer may affect the alkylation 
rates at the guanines located at positions 8-1 1 of the duplex. 
As is shown in Figure 10, the normalized bond intensities for 
cleavage at all guanine sites on the 18-mer labeled at C show 
no change in intensity as drug is added to the system. Since 
the DNase I footprinting studies established that drug binding 
is taking place, either there is no drug-induced structural 
change in DNA or there is a change but, under the conditions 
of the experiment, DMS cannot detect the change. 
Implications for the Mechanism ofActionof Chromomycin. 
It is interesting to compare the footprinting-derived binding 
constants with others in the literature. Behr et al. (1969) and 
Nayak et al. (1973) used absorption spectroscopy and 
Scatchard analysis to measure the binding constant of 
chromomycin toward calf thymus DNA. The values obtained, 
(0.92-2.0) X lo5 M-I, agreed with that recently measured for 
the related drug mithramycin using fluorescence spectroscopy. 
Chromomycin is also able to bind to chromatin but with a 
binding constant about an order of magnitude lower than for 
binding to calf thymus DNA (Nayak et al., 1975). While 
most of the reported values lie in the range 104-105 M-l, 
Itzhaki et al. (1990) reported an unusually high value of 10" 
M-I. This value was obtained by recording the optical changes 
which occur when EDTA is used to break up the chromomycin- 
Mg*+-DNA complex in solution. The reason that our 
footprinting measurements return a binding constant 2 orders 
of magnitude higher than most other determinations is unclear. 
However, footprinting directly measures the fraction of a DNA 
site blocked by drug whereas in spectral titrations this quantity 
is inferred from the optical properties of the species present 
in solution. Since there may be a number of chromomycin 
species present in solution, it is dangerous to use only optical 
methods to measure the drug's affinity. In addition, the 
binding constant to calf thymus DNA is an average over many 
binding sites, whereas the present studies consider a fragment 
which is known to possess only a single strong binding site. 
This site is unusual in the sense that it can bind two drugs 
symmetrically, a situation that is not often encountered in 
random sequence DNA. The footprinting and fluorescence 
data indicate that, at the submicromolar concentration of 
chromomycin expected in the cell, the drug probably exists 
as a monomer in solution. It is unclear if the drug is complexed 
to ions or free in vivo. However, the high concentration of 
Mg2+ in the serum and cytoplasm suggests that a magnesium 
complex is likely under cellular conditions. Since most 
potential chromomycin binding sites on natural DNA would 
not have 2-fold symmetry, it would appear that monomer and 
not dimer binding is the mode by which the drug expresses 
its antitumor properties. In this regard, monomer binding 
can clearly be seen in the early footprinting studies by Van 
Dyke and Dervan (1983) using Fe-MPE as a cleavage agent. 
However, as has been shown in our footprinting experiments, 
a DNA sequence having adjacent chromomycin sites can bind 
two drug molecules with a binding constant 2 orders of 
magnitude higher than that found for other sites in random 
sequence DNA. Thus, dimer binding may be an important 
event in vivo, especially in the promoter regions of genes, which 
are often rich in GC content. An understanding of the form 
of the drug which is present in vivo is a necessary first step 
for understanding the drug's cytotoxic and immunosuppressive 
properties. Determining which of many potential binding sites 
in gene sequences will be bound by chromomycin will require 
additional study. 
FIGURE 9: DMS/piperidine footprinting plots for the G 18-mer in 
the presence of various concentrations of chromomycin. Dashed 
curves show fits to straight lines (using all data, including intensities 
for drug concentrations not shown). Slopes divided by intercepts are 
as follows: parent band + G18, 0.0010; G6, 0.0095; G10, 0.0152; 
G11, -0.0019; G15, -0.0091. 
3 -  -ir; a-*-*-, - - V- - 0 9  * *  
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FIGURE 10: DMS/piperidine footprinting plots for the C 18-mer in 
the presence of various concentrations of chromomycin. Dashed 
curves show fits to straight lines (using all data, including intensities 
for drug concentration not shown). Slopes divided by intercepts are 
as follows: parent band, -0.0007; G16, 0.0070; G9, 0.0315; G8, 
-0.005; G4, -0.01 16. 
in the major groove by attacking N-7 of guanine (Lowley & 
Brookes, 1963), while chromomycin binds in the minor groove, 
the classic footprinting behavior (decrease of fragment 
intensities with drug concentration) was not expected. How- 
ever, the possibility existed that bound drug, by inducing a 
structural change, would alter DNA cleavage rates by DMS. 
For each concentration, all band intensities were divided by 
the total intensity to normalize them. This corrects for gel 
loading errors, etc., effectively giving a constant total amount 
of radiolabeled DNA. The normalized data for each fragment 
were then fitted to a linear function of drug concentration. 
The normalized data are shown in Figures 9 and 10 with the 
linear fits (broken lines). The relative slopes (slope/intercept) 
are close to zero in every case. Thus, no alteration in cleavage 
rates by drug is evidenced: the cutting rate is unaffected by 
drug binding. 
From the NMR studies, it has been postulated that 
chromomycin binding alters DNA structure to A-DNA (Gao 
& Patel, 1989a,b, 1990; Leroy et al., 1991). This form of 
DNA is characterized by a wide and shallow minor groove 
and a narrow but deep major groove (Dickerson et al., 1982). 
Since changes in DNA structure have been reported to 
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CONCLUSIONS 
In this manuscript we show that two chromomycin A3 
molecules bind to an oligonucleotide duplex having 2-fold 
symmetry, with a binding constant several times lo7 M-l. The 
DNase I footprinting and fluorescence data show that the 
self-association constant for the drug outside of DNA is large, - lo5 M-1. However, at  micromolar concentrations, the drug 
exists mainly as a monomer and binding of two drugs to the 
duplex takes place in a cooperative manner. Quantitative 
footprinting studies with dimethyl sulfate, which alkylates at 
N-7 of guanine located in the major groove, failed to detect 
a structural change in DNA in the chromomycin complex. 
The enhanced affinity of the drug for the 2-fold symmetric 
site suggests that sites of this type may be bound by drug in 
vivo. The results of this study, at  an earlier stage of analysis, 
have been previously published (Dabrowiak et al., 1992). 
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